Investigational New Drug (IND) Workshop

*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************

Event Details
  • Date/Time:
    • Tuesday January 23, 2018 - Wednesday January 24, 2018
      11:00 am - 12:59 pm
  • Location: Parker H. Petit Institute for Bioengineering and Bioscience, Room 1128
  • Phone: (404) 894-6228
  • URL: Petit Institute website
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact

Harold Solomon
Principal, VentureLab

Summaries

Summary Sentence: Kristen Foss, Ph.D., R.A.C. - Duke University School of Medicine

Full Summary: No summary paragraph submitted.

Kristen Foss, Ph.D., R.A.C.
Regulatory Affairs Scientist
Duke University School of Medicine


This workshop will offer best practices when conducting trials using FDA approved and unapproved drugs or substances (including biologics). It will give an overview of the IND application process and the regulatory obligations of the sponsor-investigator once an IND is filed with the FDA. Case scenarios will be presented to enhance learning and stimulate audience participation.

This workshop will address the following questions (and more):

  • What is an investigational drug?
  • Do I need an IND for my investigation? What are some examples of trials requiring an IND and examples of studies that are IND exempt?
  • When do I need an IND for an investigation using dietary supplements?
  • When should I consider having a Pre-IND meeting with the FDA?
  • What information needs to be included in my IND application?
  • What happens after I submit my IND application to the FDA?
  • What are the reporting requirements once my IND is effective?
  • How and when should I report serious adverse events (SAEs) once I have an IND?

This course is designed for anyone directly involved in conducting investigator-initiated trials:

  • Investigators
  • Regulatory Personnel
  • Clinical Research Nurses
  • Clinical Research Associates

Kristen Foss, Ph.D., received her undergraduate degree in biology from South Dakota State University and then worked as a research associate at the Translational Genomics Research Institute in Phoenix, Arizona. Foss conducted her graduate research at Duke University, where she earned her Ph.D. in Pharmacology with a certificate in Cell and Molecular Biology. During her graduate training, Foss was the recipient of a Ruth L. Kirschstein-NRSA Predoctoral Fellowship and a Robert J. Fitzgerald Scholar Award. She was also selected to participate in the Duke Scholars in Molecular Medicine Program in Oncology and Regenerative Medicine. Foss holds the US Regulatory Affairs Certification (R.A.C.) from the Regulatory Affairs Professional Society.

Related Links

Additional Information

In Campus Calendar
Yes
Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB), Wallace H. Coulter Dept. of Biomedical Engineering

Invited Audience
Faculty/Staff, Public, Graduate students, Undergraduate students
Categories
Conference/Symposium
Keywords
IBB
Status
  • Created By: Colly Mitchell
  • Workflow Status: Published
  • Created On: Nov 8, 2017 - 7:47am
  • Last Updated: Nov 8, 2017 - 8:00am